Company: Adcock Ingram
Country: South Africa
Sector: Pharmaceuticals: Major
CEO: Andy Hall
Website: Not publicly listed
Careers Page: Not publicly listed
LinkedIn: Not publicly listed
Email: Not publicly listed
Headquarters: Bryanston, Johannesburg, South Africa
Founded: 1890
Valuation/Revenue: $535.9m revenue; $447.1m market value (African Business Top 250, 2025)
Adcock Ingram is one of South Africa’s largest pharmaceutical manufacturers, producing and marketing generic and branded medicines, over-the-counter consumer health products and hospital/critical-care supplies to both private and public healthcare sectors. Listed on the Johannesburg Stock Exchange, it traces its roots to a Krugersdorp pharmacy founded in 1890.
What Does Adcock Ingram Do?
Adcock Ingram manufactures and distributes a broad portfolio spanning prescription generics, well-known consumer over-the-counter brands such as Panado (paracetamol) and Corenza C (cold and flu remedy), and hospital products including intravenous fluids and critical-care supplies used by South African public and private hospitals. Its manufacturing base gives it a resilient supply position in South Africa’s pharmaceutical market, particularly for essential medicines and hospital consumables where local production reduces dependency on imports.
Is Adcock Ingram Legit?
Yes. Adcock Ingram is a JSE-listed, well over a century-old pharmaceutical manufacturer regulated by the South African Health Products Regulatory Authority (SAHPRA), and its consumer brands like Panado are household names in South African medicine cabinets. It is a fully licensed manufacturer, not an informal or grey-market operator.
Who Owns Adcock Ingram?
South African diversified services and distribution group Bidvest is Adcock Ingram’s largest shareholder, having built a controlling stake of just over 50% by around 2021 following a period of gradual share accumulation. This followed Adcock Ingram’s earlier history as part of food and consumer group Tiger Brands, from which it was unbundled and relisted independently on the JSE in 2008. The remaining shares trade freely on the JSE among institutional and retail investors.
How Big Is Adcock Ingram?
According to African Business magazine’s Top 250 companies in Africa list for 2025, Adcock Ingram generated revenue of roughly $536 million against a market value of about $447 million, ranking 150th among Africa’s largest companies. The company’s revenue mix spans its OTC consumer brands, prescription/generic medicines, and hospital products divisions, with periodic drug shortages and currency-linked input cost pressure among the recurring themes in its results given reliance on imported active pharmaceutical ingredients.
Who Is the CEO of Adcock Ingram?
Andy Hall has served as chief executive officer of Adcock Ingram since 2017, succeeding long-serving former CEO Jonathan Louw, and has overseen the company’s operations through Bidvest’s rise to majority ownership as well as periods of heightened demand tied to South African public health needs.
Is Adcock Ingram Publicly Traded?
Yes. Adcock Ingram trades on the JSE under the ticker AIP and is one of the exchange’s principal pharmaceutical sector stocks, though Bidvest’s majority stake means free-float liquidity is more limited than for a fully independent widely held company.
What Has Adcock Ingram Been in the News For Recently?
Adcock Ingram has periodically featured in South African healthcare-sector coverage relating to medicine shortages, generic drug pricing regulation, and the broader rollout debate around South Africa’s National Health Insurance (NHI) scheme, which could materially affect pharmaceutical demand patterns and pricing if implemented. Its majority ownership by Bidvest has also drawn periodic market speculation about whether Bidvest might eventually seek to take the company fully private, though no such transaction has been confirmed here.
Links
Website: Not publicly listed
Careers Page: Not found
LinkedIn: Not found
Email: Not publicly listed
FAQ
Is Adcock Ingram legit? Yes, it is a JSE-listed, SAHPRA-regulated pharmaceutical manufacturer operating since 1890.
Who owns Adcock Ingram? Bidvest holds a controlling stake of just over 50%, with the remainder publicly traded.
Who is the CEO of Adcock Ingram? Andy Hall, since 2017.
How big is Adcock Ingram? Revenue of about $536 million and market value near $447 million per African Business’s 2025 Top 250 ranking.
What brands does Adcock Ingram make? Panado, Corenza C and various generic medicines and hospital products, among others.
Is Adcock Ingram publicly traded? Yes, on the JSE under ticker AIP.